Retatrutide (LY3437943) is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, currently in phase 3 clinical trials
The Role of a Personalized Program Weight loss is about more than just a shot once a week
Same-day shipping when ordered by 2pm Central Time, MondayFriday
Prescription validation: If you do not have a current prescription, we facilitate a secure, online assessment with a Canadian-licensed healthcare providerno in-person appointment required
MC4R (energy homeostasis, CNS): Both peptides are potent MC4R agonists
According to FDA prescribing information, gastrointestinal adverse effects occur in a substantial proportion of patients, particularly during dose initiation and escalation